RegulatoryCNBC-TV18
Aurobindo Pharma snaps 12-day winning streak after USFDA update on subsidiary's API unit
Negative-46
GreyOak summary
Aurobindo Pharma shares fell nearly 2% after the USFDA issued a Form 483 with a 'Voluntary Action Indicated' classification for its subsidiary Apitoria Pharma's API facility.
What it affects
- Aurobindo PharmaAUROPHARMANegative -46
Shares fell after USFDA inspection issues.Rolling sentiment Negative -25
Source
Read the original at CNBC-TV18More Aurobindo Pharma news
- Aurobindo Pharma shares extend losses after USFDA OAICNBC-TV18 · Regulatory ·
- USFDA classifies Aurobindo Pharma's US facility as 'official action indicated'Economic Times · Regulatory ·
- Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDAEconomic Times · Regulatory ·
- Helios Mid Cap Fund adds Aurobindo Pharma, increases stake in PaytmEconomic Times · Company update ·